Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 3/2013

01.09.2013 | Lymphomas (C Dearden, Section Editor)

T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway

verfasst von: Kathrin Warner, Nicole Weit, Giuliano Crispatzu, Joan Admirand, Dan Jones, Marco Herling

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

T-cell receptor (TCR) signaling is pivotal in T-cell development and function. In peripheral T-cell lymphomas/leukemias (PTCL/L), histogenesis, transforming events, epidemiology, and clinical presentation are also closely linked to TCR-mediated influences. After reviewing the physiology of normal TCR signaling and cellular responses, we describe here the association of subgroups of PTCL/L with specific patterns of TCR activation as relevant tumor-initiating and/or tumor-sustaining programs. We identify PTCL/L with a functionally intact TCR machinery in which stimulation is possibly incited by exogenous antigens or autoantigens. Distinct from these are tumors with autonomous oncogenic signaling by dysregulated TCR components uncoupled from extrinsic receptor input. A further subset is characterized by transforming events that activate molecules acting as substitutes for TCR signaling, but triggering similar downstream cascades. We finally discuss the consequences of such a functional model for TCR-targeted therapeutic strategies including those that are being tested in the clinic and those that still require further development.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2.
Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.PubMedCrossRef
3.
• Pileri SA, Piccaluga PP. New molecular insights into peripheral T cell lymphomas. J Clin Invest. 2012;122(10):3448–55. This is an up-to-date review by experts from the European T-Cell Lymphoma Study Group on our current concepts of the molecular pathogenesis and histogenesis of major subsets of nodal peripheral T-cell lymphomas.PubMedCrossRef
4.
Smith-Garvin J, Koretzky G, Jordan M. T cell activation. Annu Rev Immunol. 2009;27:591–619.PubMedCrossRef
5.
Acuto O, Di Bartolo V, Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol. 2008;8(9):699–712.PubMedCrossRef
6.
Baker M, Gamble J, Tooze R, et al. Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. EMBO J. 2000;19(17):4644–54.PubMedCrossRef
7.
Nakayama T, Yamashita M. The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin Immunol. 2010;22(5):303–9.PubMedCrossRef
8.
Jones D, O’Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96(2):685–90.PubMed
9.
Zhou L, Chong MMW, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009;30(5):646–55.PubMedCrossRef
10.
Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123(4):758–62.PubMedCrossRef
11.
Boyman O, Létourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol. 2009;39(8):2088–94.PubMedCrossRef
12.
13.
Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532–42.PubMedCrossRef
14.
An J, Fujiwara H, Suemori K, et al. Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis. Int J Hematol. 2011;93(2):176–85.PubMedCrossRef
15.
Crispín JC, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev. 2009;8(3):190–5.PubMedCrossRef
16.
Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res. 2002;160:271–80.PubMedCrossRef
17.
Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4(3):211–22.PubMedCrossRef
18.
Morgan SM, Hodges E, Mitchell TJ, et al. Molecular analysis of T-cell receptor β genes in cutaneous T-cell lymphoma reveals Jβ1 bias. J Invest Dermatol. 2006;126(8):1893–9.PubMedCrossRef
19.
Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(16):4812–21.PubMedCrossRef
20.
Dummer R, Geertsen R, Ludwig E, Niederer E, Burg G. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leuk Lymphoma. 1998;28(5–6):515–22.PubMed
21.
Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709–18.PubMedCrossRef
22.
Abdulla F, Duvic M, Kim Y. T-cell lymphomas. Totowa, NJ: Humana Press; 2013.
23.
Martínez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254–63.PubMedCrossRef
24.
Wlodarski MW, O’Keefe C, Howe EC, et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106(8):2769–80.PubMedCrossRef
25.
Garrido P, Ruiz-Cabello F, Bárcena P, et al. Monoclonal TCR-Vβ13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood. 2007;109(11):4890–8.PubMedCrossRef
26.
Lima M, Almeida J, Santos AH, et al. Immunophenotypic analysis of the TCR-vβ repertoire in 98 persistent expansions of CD3+/TCR-αβ + large granular lymphocytes. Am J Pathol. 2001;159(5):1861–8.PubMedCrossRef
27.
Sandberg Y, Almeida J, Gonzalez M, et al. TCRγ/δ + large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRγ/δ + T-cells. Leukemia. 2006;20(3):505–13.PubMedCrossRef
28.
O’Keefe CL, Plasilova M, Wlodarski M, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004;172(3):1960–9.PubMed
29.
Sandberg Y. Basic and clinical aspects of the T-cell receptor in mature T-cell malignancies. Ph.D. Thesis. Erasmus University Rotterdam; 2007. p. 221.
30.
•• Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118(16):4384–93. This paper instructively shows for T-LGL what many researchers in the field of mature T-cell lymphomas have been observing, namely a marked clonal dynamics of retraction and expansion of various TCR-defined clones within one tumor. It also contributes particularly to our understanding of T-LGL representing a spectrum of gradual overlap between reactive lesions and overt malignant neoplasms.PubMedCrossRef
31.
Davey MP, Starkebaum G, Loughran TP. CD3+ leukemic large granular lymphocytes utilize diverse T-cell receptor Vβ genes. Blood. 1995;85(1):146–50.PubMed
32.
Loughran TP, Hadlock KG, Perzova R, et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998;101(2):318–24.PubMedCrossRef
33.
Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003;102(12):4059–66.PubMedCrossRef
34.
Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion. Blood. 1997;89(1):32–40.PubMed
35.
Abrams JT, Balin BJ, Vonderheid EC. Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:69–85.PubMedCrossRef
36.
Tissier F, Martinon F, Camilleri-Broët S, et al. T-cell receptor Vβ repertoire in nodal non-anaplastic peripheral T-cell lymphomas. Pathol Res Pract. 2002;198(6):389–95.PubMedCrossRef
37.
Hodges E, Edwards SE, Howell WM, Smith JL. Polymerase chain reaction amplification analyses of clonality in T-cell malignancy including peripheral T-cell lymphoma. Leukemia. 1994;8(2):295–8.PubMed
38.
Tembhare P, Yuan CM, Xi L, et al. Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis. Am J Clin Pathol. 2011;135(6):890–900.PubMedCrossRef
39.
•• Newrzela S, Al-Ghaili N, Heinrich T, et al. T-cell receptor diversity prevents T-cell lymphoma development. Leukemia. 2012;26(12):2499–507. Mature T cells have been considered to be largely resistant to (experimental) transformation by most known T-cell oncogenes. However, these researchers present data that indicate that in a background of clonal T-cell restriction, as for example observed during senescence or in lymphopenia, the outgrowth of mature T-cell lymphomas is facilitated. This supports a model in which homeostatic mechanisms that stabilize the diversity of the normal T-cell repertoire, e.g. clonal competition, also control the emergence of potentially malignant T-cell clones.PubMedCrossRef
40.
• Geissinger E, Sadler P, Roth S, et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica. 2010;95(10):1697–704. This study shows that severely altered expression of the TCR/CD3 complex, of TCR-associated transcription factors, and of signal transduction molecules is common and a shared characteristic in CD30 + T-cell lymphomas. This distinguishes these tumors from other subsets, e.g. PTCL-nos, and supports the TCR-based concept of a functional categorization of mature T-cell tumors outlined here.PubMedCrossRef
41.
Admirand J, Herling M, Patel K, et al. T-cell receptor signaling and growth pathways in T-cell tumors. Mod Pathol. 2005;18:220A.CrossRef
42.
Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328–37.PubMedCrossRef
43.
Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328–35.PubMedCrossRef
44.
Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-γ levels through phosphatidylinositol 3-kinase and protein kinase c pathway activation. J Immunol. 2005;175(2):864–73.PubMed
45.
Herling M, Patel KA, Weit N, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009;114(21):4675–86.PubMedCrossRef
46.
Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20(2):313–8.PubMedCrossRef
47.
Feldman AL, Sun DX, Law ME, et al. Overexpression of SYK tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139–43.PubMedCrossRef
48.
Travert M, Huang Y, De Leval L, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood. 2012;119(24):5795–806.PubMedCrossRef
49.
Ortiz S, Lee W, Smith D, et al. Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells. Exp Biol Med (Maywood). 2010;235(12):1450–63.PubMedCrossRef
50.
• Pechloff K, Holch J, Ferch U, et al. The fusion kinase ITK-SYK mimics a T-cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T-cell lymphoma. J Exp Med. 2010;207(5):1031–44. In the context of the recurrence of the t(5;9)(q33;q22) in a subset of PTCL-nos and the frequently high levels of SYK across many mature T-cell tumors, these authors provide experimental evidence of the transforming capacity of the ITK-SYK fusion tyrosine kinase in peripheral T-cells. Their work supports our TCR-based model by showing that constitutive TCR signaling is a strong oncogenic force.PubMedCrossRef
51.
Dierks C, Adrian F, Fisch P, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 2010;70(15):6193–204.PubMedCrossRef
52.
Amin HM, Lai R. Pathobiology of ALK + anaplastic large-cell lymphoma. Blood. 2007;110(7):2259–67.PubMedCrossRef
53.
Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):511–9.PubMedCrossRef
54.
Hiromura M, Okada F, Obata T, et al. Inhibition of AKT kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem. 2004;279(51):53407–18.PubMedCrossRef
55.
Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T-cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:106–22.PubMedCrossRef
Metadaten
Titel
T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway
verfasst von
Kathrin Warner
Nicole Weit
Giuliano Crispatzu
Joan Admirand
Dan Jones
Marco Herling
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2013
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-013-0165-2

Weitere Artikel der Ausgabe 3/2013

Current Hematologic Malignancy Reports 3/2013 Zur Ausgabe

Lymphomas (C Dearden, Section Editor)

Hairy Cell Leukemia—New Genes, New Targets

Lymphomas (P McLaughlin, Section Editor)

Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience

Lymphomas (J Armitage, Section Editor)

Surveillance Imaging in Pediatric Hodgkin Lymphoma

Lymphomas (P McLaughlin, Section Editor)

The Role of Radiation Therapy in the Treatment of Stage I-II Diffuse Large B-Cell Lymphoma

Lymphomas (C Dearden, Section Editor)

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis

Lymphomas (C Dearden, Section Editor)

Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise